Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer

Journal of the National Cancer Institute

Volumn 107, Issue 8, 2015, Pages

  Patel, Sunita K ^a   Wong, Andrew L ^a   Wong, F Lennie ^a   Breen, Elizabeth Crabb ^c   Hurria, Arti ^a   Smith, Mackenzie ^a   Kinjo, Christine ^a   Paz, I Benjamin ^a   Kruper, Laura ^a   Somlo, George ^a   Mortimer, Joanne E ^a   Palomares, Melanie R ^a   Irwin, Michael R ^c   Bhatia, Smita ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TYPE II; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; TUMOR MARKER; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CHARLSON COMORBIDITY INDEX; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HUMAN; INFLAMMATION; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MOOD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; AFFECT; AGED; BLOOD; BREAST NEOPLASMS; COMPARATIVE STUDY; INFLAMMATORY BREAST CANCER; MEMORY; MIDDLE AGED; POSTMENOPAUSE; PSYCHOLOGY; QUESTIONNAIRE;

AFFECT; AGED; BIOMARKERS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COGNITION; COMORBIDITY; EXECUTIVE FUNCTION; FATIGUE; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SURVEYS AND QUESTIONNAIRES;

EID: 84939620146     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv131     Document Type: Article

References (44)

1. Tannock IF, Ahles TA, Ganz PA, et al. Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. J Clin Onc. 2004;22(11):2233-2239.
2. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292-2299.
3. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer. Cancer. 2007;109(9):1905-1913.
4. Bostjan S, Haibo Z, Berstein L, et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887-899.
5. McAfoose J, Baune BT. Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev. 2009;33(3):355-366.
6. Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5):445-452.
7. Lauta VM. A review of the cytokine network in multiple myeloma: Diagnostic, prognostic, and therapeutic implications. Cancer. 2003;97(10):2440-2452.
8. Rutkowski P, Kamińska J, Kowalska M, et al. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis. J Surg Onc. 2003;84(3):151-159.
9. Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J. Potential prognostic and therapeutic roles for cytokines in breast cancer (review). Oncol Rep. 2006;15(1):179-185.
10. Tsavaris N, Kosmas C, Vadiaka M, et al. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87(1):21-27.
11. Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12(9):2759-2766.
12. Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(suppl):S109-S116.
13. Kahn AL, Larsen F, Heys SD, et al. Peri-operative acute phase response and cytokine release in women with breast cancer: Modulation by polyadenylic-polyuridylic acid. Eur J Surg Onc. 1999;25(6):574-579.
14. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev. 2008;29(4):494-511.
15. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672-2713.
16. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788-793.
17. Willis C, Morris JM, Danis V, et al. Cytokine production by peripheral blood monocytes during the normal human ovulatory menstrual cycle. Hum Reprod. 2003;18(6):1173-1178.
18. O'Connor MF, Bower JE, Cho HJ, et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun. 2009;23(7):887-897.
19. Braithwaite D, Tammemagi CM, Moore, DH, et al. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009;124(5):1213-1219.
20. Wefel JS, Vardy J, Ahles T, et al. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703-708.
21. Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110(1):143-152.
22. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System: Technical Manual. San Antonio, TX: The Psychological Corporation; 2001.
23. Brandt J, Benedict HB. The Hopkins Verbal Learning Test-Revised: Professional Manual. Lutz, FL: Psychological Assessment Resources; 2001.
24. th ed. San Antonio, TX: Pearson; 2008.
25. Donovan KA, Jacobsen PB, Small BJ, et al. Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory. J Pain Symptom Manage. 2008;36(5):480-487.
26. Derogatis LR. The Brief Symptom Inventory 18 (BSI 18): Administration, Scoring and Procedures Manual. Minneapolis, MN: National Computer Systems Pearson; 2001.
27. Berman MG, Askren MK, Jung M, et al. Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychol. 2014;33(3):222-231.
28. Arend WP, Malyak M, Guthridge CJ, et al. Interleukin-1 receptor antagonist: role in biology. Annu Rev of Immunol. 1998;16(1):27-55.
29. Diez-Ruiz A, Tilz GP, Zangerle R, et al. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Hematol. 1995;54(1):1-8.
30. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7(3):231-240.
31. Eysenck M, Derakshan N, Santos R, Calvo MG. Anxiety and cognitive performance: attentional control theory. Emotion. 2007;7(2):336-353.
32. Gunstad J, Paul RH, Cohen RA, et al. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry. 2007;48(1):57-61.
33. Walther K, Birdsill AC, Glisky EL, et al. Structural brain differences and cognitive functioning related to body mass index in older females. Hum Brain Mapp. 2010;31(7):1052-1064.
34. Mandelblatt JS, Stern RA, Luta G, et al. Cognitive impairment in older patients with breast cancer before systemic therapy: is there an interaction between cancer and comorbidity? J Clin Onc. 2014;32(18):1909-1918.
35. Ganz, PA, Bower JE, Kwan L, et al. Does tumor necrosis factor-alhpa (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain, Behav Immun. 2013;30(suppl):S99-S108.
36. Pickering M, O'Connor JJ. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog Brain Res. 2007;163:339-354.
37. Schobitz B, De Kloet ER, Holsboer F. Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog in Neurobiol. 1994;44(4):397-432.
38. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann of Neurol. 1988;23(4):339-346.
39. Buntinx M, Gielen E, Van Hummelen P, et al. Cytokine-induced cell death in human oligodendroglial cell lines. II: alterations in gene expression induced by interferon-ã and tumor necrosis factor-α. J Neurosci Res. 2004;76(6):846-861.
40. Sudheimer KD, O'hara R, Spiegel D, et al. Cortisol, cytokines, and hippocampal volume interactions in the elderly. Front Aging Neurosci. 2014;6:1-7.
41. Dunn AJ. Mechanisms by which cytokines signal the brain. Int Rev Neurobiol. 2002;52:43-65.
42. Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010;7(12):686-698.
43. Raz N, Rodrigue KM, Kennedy KM, et al. Vascular health and longitudinal changes in brain and cognitive in middle-aged and older adults. Neuropsychology. 2007;21(2):149-157.
44. Uiterwijk R, Huijts M, Staals J, et al. Subjective cognitive failures in patients with hypertension are related to cognitive performance and cerebral microbleeds. Hypertension. 2014;64(3):653-657.